# Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

> **NCT05079282** · PHASE1 · RECRUITING · sponsor: **Ono Pharmaceutical Co., Ltd.** · enrollment: 217 (estimated)

## Conditions studied

- Relapsed or Refractory T Cell Lymphoma

## Interventions

- **DRUG:** ONO-4685

## Key facts

- **NCT ID:** NCT05079282
- **Lead sponsor:** Ono Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-10
- **Primary completion:** 2027-08-31
- **Final completion:** 2028-08-31
- **Target enrollment:** 217 (ESTIMATED)
- **Last updated:** 2026-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05079282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05079282, "Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05079282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*